Cyclosporine, blood pressure and atherosclerosis

Stephen C Textor, Sandra J Taler, V. J. Canzanello, L. Schwartz

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Blood pressure rises soon after administration of immunosuppressive regimens using cyclosporin A. These changes lead to widespread vasoconstriction and increased risk for atherosclerosis. Changes in blood pressure are commonly associated with disturbed circadian regulation and may produce rapidly developing target injury, including intracranial hemorrhage, left ventricular hypertrophy and microangiopathic hemolysis. Mechanisms underlying this disorder are complex and include altered vascular endothelial function. Vasodilators such as prostacyclin and nitric oxide are suppressed, whereas vasoconstrictors, including endothelin, are increased. Changes in the kidney include vasoconstriction, reduced glomerular filtration and sodium excretion. When blood pressure effects are combined with the effects of glucocorticoids and weight gain, changes in cholesterol and triglycerides magnify the risk for atherosclerotic disease. Effective therapy depends upon rigorous blood pressure control and administration of vasodilating agents with attention to the interactions with cyclosporin A. Effective blood pressure control and lipid management is an important component in the long- term management of transplant recipients.

Original languageEnglish (US)
Pages (from-to)141-151
Number of pages11
JournalCardiology in Review
Volume5
Issue number3
StatePublished - 1997

Fingerprint

Cyclosporine
Atherosclerosis
Blood Pressure
Vasoconstriction
Intracranial Hemorrhages
Endothelins
Left Ventricular Hypertrophy
Vasoconstrictor Agents
Epoprostenol
Immunosuppressive Agents
Hemolysis
Vasodilator Agents
Glucocorticoids
Weight Gain
Blood Vessels
Nitric Oxide
Triglycerides
Sodium
Cholesterol
Kidney

Keywords

  • Atherosclerosis
  • Blood pressure
  • Circadian rhythm
  • Cyclosporin A
  • Endothelin
  • Vasodilating agents

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Cyclosporine, blood pressure and atherosclerosis. / Textor, Stephen C; Taler, Sandra J; Canzanello, V. J.; Schwartz, L.

In: Cardiology in Review, Vol. 5, No. 3, 1997, p. 141-151.

Research output: Contribution to journalArticle

Textor, SC, Taler, SJ, Canzanello, VJ & Schwartz, L 1997, 'Cyclosporine, blood pressure and atherosclerosis', Cardiology in Review, vol. 5, no. 3, pp. 141-151.
Textor, Stephen C ; Taler, Sandra J ; Canzanello, V. J. ; Schwartz, L. / Cyclosporine, blood pressure and atherosclerosis. In: Cardiology in Review. 1997 ; Vol. 5, No. 3. pp. 141-151.
@article{bf139c656ca549adb56e97268dc34549,
title = "Cyclosporine, blood pressure and atherosclerosis",
abstract = "Blood pressure rises soon after administration of immunosuppressive regimens using cyclosporin A. These changes lead to widespread vasoconstriction and increased risk for atherosclerosis. Changes in blood pressure are commonly associated with disturbed circadian regulation and may produce rapidly developing target injury, including intracranial hemorrhage, left ventricular hypertrophy and microangiopathic hemolysis. Mechanisms underlying this disorder are complex and include altered vascular endothelial function. Vasodilators such as prostacyclin and nitric oxide are suppressed, whereas vasoconstrictors, including endothelin, are increased. Changes in the kidney include vasoconstriction, reduced glomerular filtration and sodium excretion. When blood pressure effects are combined with the effects of glucocorticoids and weight gain, changes in cholesterol and triglycerides magnify the risk for atherosclerotic disease. Effective therapy depends upon rigorous blood pressure control and administration of vasodilating agents with attention to the interactions with cyclosporin A. Effective blood pressure control and lipid management is an important component in the long- term management of transplant recipients.",
keywords = "Atherosclerosis, Blood pressure, Circadian rhythm, Cyclosporin A, Endothelin, Vasodilating agents",
author = "Textor, {Stephen C} and Taler, {Sandra J} and Canzanello, {V. J.} and L. Schwartz",
year = "1997",
language = "English (US)",
volume = "5",
pages = "141--151",
journal = "Cardiology in Review",
issn = "1061-5377",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Cyclosporine, blood pressure and atherosclerosis

AU - Textor, Stephen C

AU - Taler, Sandra J

AU - Canzanello, V. J.

AU - Schwartz, L.

PY - 1997

Y1 - 1997

N2 - Blood pressure rises soon after administration of immunosuppressive regimens using cyclosporin A. These changes lead to widespread vasoconstriction and increased risk for atherosclerosis. Changes in blood pressure are commonly associated with disturbed circadian regulation and may produce rapidly developing target injury, including intracranial hemorrhage, left ventricular hypertrophy and microangiopathic hemolysis. Mechanisms underlying this disorder are complex and include altered vascular endothelial function. Vasodilators such as prostacyclin and nitric oxide are suppressed, whereas vasoconstrictors, including endothelin, are increased. Changes in the kidney include vasoconstriction, reduced glomerular filtration and sodium excretion. When blood pressure effects are combined with the effects of glucocorticoids and weight gain, changes in cholesterol and triglycerides magnify the risk for atherosclerotic disease. Effective therapy depends upon rigorous blood pressure control and administration of vasodilating agents with attention to the interactions with cyclosporin A. Effective blood pressure control and lipid management is an important component in the long- term management of transplant recipients.

AB - Blood pressure rises soon after administration of immunosuppressive regimens using cyclosporin A. These changes lead to widespread vasoconstriction and increased risk for atherosclerosis. Changes in blood pressure are commonly associated with disturbed circadian regulation and may produce rapidly developing target injury, including intracranial hemorrhage, left ventricular hypertrophy and microangiopathic hemolysis. Mechanisms underlying this disorder are complex and include altered vascular endothelial function. Vasodilators such as prostacyclin and nitric oxide are suppressed, whereas vasoconstrictors, including endothelin, are increased. Changes in the kidney include vasoconstriction, reduced glomerular filtration and sodium excretion. When blood pressure effects are combined with the effects of glucocorticoids and weight gain, changes in cholesterol and triglycerides magnify the risk for atherosclerotic disease. Effective therapy depends upon rigorous blood pressure control and administration of vasodilating agents with attention to the interactions with cyclosporin A. Effective blood pressure control and lipid management is an important component in the long- term management of transplant recipients.

KW - Atherosclerosis

KW - Blood pressure

KW - Circadian rhythm

KW - Cyclosporin A

KW - Endothelin

KW - Vasodilating agents

UR - http://www.scopus.com/inward/record.url?scp=0030984411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030984411&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0030984411

VL - 5

SP - 141

EP - 151

JO - Cardiology in Review

JF - Cardiology in Review

SN - 1061-5377

IS - 3

ER -